ST Renfu Subsidiary Yichang Humanwell Receives Drug Registration Certificate for Brexpiprazole Tablets

Jiemian··CN·Read original
2▲1 ▼0Impact / 5
Summary · why it matters

ST Renfu announced that its holding subsidiary Yichang Humanwell Pharmaceutical recently received the drug registration certificate for Brexpiprazole Tablets approved by the National Medical Products Administration. The specifications include 0.5 mg, 1 mg, and 2 mg, with a registration classification of chemical drug category 4, and the approval number is valid until July 27, 2031. The drug is mainly used for the treatment of schizophrenia in adults. The original product was developed by Otsuka Pharmaceutical and was approved for marketing in China in 2024.

Impact on assets 1

Others▲ · 1 stocks
© 2026 MarketIVNews